NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer
Metrics: PDF 1009 views | HTML 1677 views | ?
Yifang Wei1,*, Shentong Yu1,2,*, Yongping Zhang3,*, Yuan Zhang4, Huadong Zhao5, Zhixiong Xiao6, Libo Yao1, Suning Chen1,7, Jian Zhang1
1State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi’an, 710032, Shaanxi, China
2Department of Pathology, The Fourth Military Medical University, Xi’an, 710032, Shaanxi, China
3Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, 310058, Hangzhou, China
4Department of Oncology, The State Key Discipline of Cell Biology, Xijing Hospital, The Fourth Military Medical University, Xi’an, 710032, Shaanxi, China
5Department of General Surgery, Tangdu Hospital, The Fourth Military Medical University, 710038, Xi’an, China
6College of Life Science, Sichuan University, Chendu, 610065, Sichuan, China
7Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an, 710032, Shaanxi, China
*These authors have contributed equally to this work
Jian Zhang, email: email@example.com
Suning Chen, email: firstname.lastname@example.org
Libo Yao, email: email@example.com
Keywords: NDRG2, P53, Bad, chemotherapy resistance, breast cancer
Abbreviations: NDRG2, N-Myc downstream regulated gene 2; ADR, Adriamycin; ABC, ATP-Binding Cassette
Received: December 05, 2016 Accepted: February 20, 2017 Published: March 09, 2017
Chemo-resistance presents a difficult challenge for the treatment of breast cancer. Our previous study showed that N-Myc downstream-regulated gene 2 (NDRG2) is involved in p53-mediated apoptosis induced by chemotherapy, through a mechanism that has so far remained obscure. Here, we explored the role of NDRG2 in chemo-resistance with a focus on Adriamycin (ADR) and found that NDRG2 expression decreased in ADR resistance breast cancer cells. Interestingly, NDRG2 can promote ADR sensitivity by inhibiting proliferation, enhancing cellular damage responses, and promoting apoptosis in a p53-dependent manner. We also found that NDRG2 could upregulate Bad expression by increasing its half-life, which is associated with p53 to mitochondria. Hence, our collective data provided the ﬁrst evidence that NDRG2 promoting sensitivity of breast cancer is dependent on p53 by preventing p53 from entering the nucleus rather than changing its expression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.